Skip to main navigation
For additional product information, please see

Product Information

  • AviseTest.com

Contact Us

  • Contact Us

Social

X
Exagen Diagnostics - Logo
  • About Exagen
    • Exagen Quality
    • Lab Certifications
  • Our Products
    • AVISE CTD
      • SLE & Connective Tissue Disease Test
    • AVISE Lupus
      • SLE Diagnostic Test
    • AVISE SLE Monitor
      • SLE Disease Monitoring Test
    • AVISE SLE Prognostic
      • SLE Prognostic Test
    • AVISE APS
      • Antiphospholipid Syndrome Test
    • AVISE MTX
      • Methotrexate Polyglutamate Measuring Test
    • AVISE HCQ
      • The Hydroxychloroquine (HCQ) test measuring drug levels in whole blood
    • AVISE Anti-CarP
      • RA Diagnosis & Prognosis
  • Our People
    • Leadership
    • Board of Directors
    • Careers
  • Our Science
    • CB-CAPs – Lupus Biomarkers
    • Clinical Trials
    • Research & Development
    • Publications
  • Business Development
    • Business Development
    • Partners
  • ESG
    • Corporate Governance
    • ESG Report
  • Investors

    Investor Relations

    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Annual Report
    • SEC Filings
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Investor Contacts
    • Email Alerts
Image

SEC Filing Details

SEC Filing Details

Document Details

Form
4
Filing Date
Sep 23, 2019
Document Date
Sep 19, 2019
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Exagen
Issuer
EXAGEN INC.
Filer
TULLIS DICKERSON CAPITAL FOCUS III, L.P.

Filing Formats

View HTML
Download PDF
Download DOC
Print Page
Email Alerts
RSS Feeds
Investor Contacts
© 2026 Exagen Inc. | All Rights Reserved

Footer

  • Terms of Use
  • Notice of Privacy Practices
  • Lab Certifications
  • Contact Us

Social

X
Image

© 2026 Exagen Inc. | All Rights Reserved

Footer

  • Terms of Use
  • Notice of Privacy Practices
  • Lab Certifications
  • Contact Us

Social

X
Exagen Quality Seal
  • About Exagen
    • ← Back
    • Exagen Quality
    • Lab Certifications
  • Our Products
    • ← Back
    • AVISE CTD
      • ← Back
      • SLE & Connective Tissue Disease Test
    • AVISE Lupus
      • ← Back
      • SLE Diagnostic Test
    • AVISE SLE Monitor
      • ← Back
      • SLE Disease Monitoring Test
    • AVISE SLE Prognostic
      • ← Back
      • SLE Prognostic Test
    • AVISE APS
      • ← Back
      • Antiphospholipid Syndrome Test
    • AVISE MTX
      • ← Back
      • Methotrexate Polyglutamate Measuring Test
    • AVISE HCQ
      • ← Back
      • The Hydroxychloroquine (HCQ) test measuring drug levels in whole blood
    • AVISE Anti-CarP
      • ← Back
      • RA Diagnosis & Prognosis
    • AVISE PC4d
      • ← Back
      • History of SLE Thrombosis
  • Our People
    • ← Back
    • Leadership
    • Board of Directors
    • Careers
  • Our Science
    • ← Back
    • CB-CAPs – Lupus Biomarkers
    • Clinical Trials
    • Research & Development
    • Publications
  • Business Development
    • ← Back
    • Business Development
    • Partners
  • ESG
    • ← Back
    • Corporate Governance
    • ESG Report
  • Investors

    Investor Relations

    • ← Back
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Annual Report
    • SEC Filings
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Investor Contacts
    • Email Alerts